Compare MobilEye Global Inc (MBLY) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MobilEye Global Inc vs Novavax Inc — how do they compare? MobilEye Global Inc trades at $7.1 (market cap $6.00B), while Novavax Inc trades at $12.75 (market cap $1.82B). The key difference: MobilEye Global Inc is far larger — about 3.3× Novavax Inc's market cap, and Novavax Inc is trading nearer its 52-week high, MobilEye Global Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold MobilEye Global Inc for 15 Days and Novavax Inc for 59 Days on average.
| MBLY | NVAX | |
|---|---|---|
Market Cap | $6.00B | $1.82B |
Volume | 7,007,849 | 6,198,505 |
Sector | Consumer Cyclical | Health |
52-Week High | $15.42 | $12.75 |
52-Week Low | $6.56 | $6.22 |
Typical Hold Time | 15 Days | 59 Days |
Enterprise Value | $4.56B | $1.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mobileye Global (MBLY) trades at $7.06, down 1.26% with bearish technical signals despite recent earnings beats. The company shows strong revenue growth to $1.9B in 2025 but faces significant profitability challenges with a -201.49% net income margin. Analyst consensus leans bullish with a $10.83 price target, while institutional activity shows mixed positioning amid autonomous driving sector volatility.
MBLY presents a high-risk opportunity with substantial upside potential if profitability improves, but current negative margins and bearish technicals suggest caution. The autonomous driving market position remains strong, though execution risks and competitive pressures could limit near-term gains despite Wall Street's optimistic price targets.
Novavax (NVAX) trades at $11.01, down 1.87% on the day, with a bullish technical signal from moving averages and a strong buy consensus from analysts (73.9% buy ratings). The company reported a net income of $440.3M in 2025, a significant turnaround from prior losses, though 2026 projections show a return to negative margins. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivots toward its Matrix-M adjuvant platform through partnerships.
The outlook is mixed: near-term catalysts include partnership-driven growth and vaccine approvals, but persistent cash burn and projected 2026 losses pose risks. Investor sentiment is buoyed by recent earnings beats and strategic shifts, yet execution on profitability remains critical for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MobilEye Global Inc
Mobileye Global Inc. is a global leader in the development and deployment of Advanced Driver Assistance Systems (ADAS) and autonomous driving technologies. The company specializes in computer vision, machine learning, and data analysis to create sensing, mapping, and driving policy solutions. Mobileye's technology, including its EyeQ system-on-chips and its crowd-sourced mapping platform (REM), is integrated into vehicles worldwide, aiming to improve road safety and enable the future of autonomous mobility.
Read more on MBLY →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
